📄 Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2.

A newly identified novel coronavirus (SARS-CoV-2) is causing pneumonia-associated respiratory syndrome across the world. Epidemiology, genomics, and pathogenesis of the SARS-CoV-2 show high homology with that of SARS-CoV. Current efforts are focusing on development of specific antiviral drugs. Therapeutic neutralizing antibodies (NAbs) against SARS-CoV-2 will be greatly important therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19). Herein, the host immune responses against SARS-CoV discussed in this review provide implications for developing NAbs and understanding clinical interventions against SARS-CoV-2. Further, we describe the benefits, challenges and considerations of NAbs against SARS-CoV-2. Although many challenges exist, NAbs still offer a therapeutic option to control the current pandemic and the possible re-emergence of the virus in the future, and their development therefore remains a high priority.

keywords 🔗 *COVID-19 (1240) 🔗 *Neutralizing antibody (88) 🔗 *SARS-CoV-2 (551) 🔗 *severe acute respiratory syndrome (1654) 🔗 neutralizing antibodies (122) 🔗 novel coronavirus (684) 🔗 immune response (314) 🔗 immune responses (142) 🔗 respiratory syndrome (2004)

download 🔖 [BibTeX]